Alembic Pharma Gains USFDA Approval for Parkinson's Therapy

has secured final approval from the US Food and Drug Administration (USFDA) for its generic Carbidopa, Levodopa, and Entacapone tablets, a combination therapy for Parkinson's disease management. This abbreviated new drug application (ANDA) matches the reference product Stalevo from Orion Corporation and comes in strengths such as 12.5 mg/50 mg/200 mg and 25 mg/100 mg/200 mg. The approval bolsters Alembic's US portfolio, now totaling 234 ANDAs with 214 final and 20 tentative nods, highlighting its expertise in complex generics. It enables market entry into a key segment for treating Parkinson's symptoms, potentially driving revenue growth amid rising demand for affordable options. Disclaimer: This post is for informational purposes only and not a recommendation to buy or sell any securities. I, or my family, associates, or relatives, may have a financial interest in the securities mentioned.